Vericel
Logotype for Vericel Corporation

Vericel (VCEL) investor relations material

Vericel 2026 Stephens Annual Investment Conference | NASH2026 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Vericel Corporation
2026 Stephens Annual Investment Conference | NASH2026 summary18 Nov, 2026

Q3 performance

  • Q3 2026 revenue topped $85M, up 26% YoY and above guidance; MACI revenue exceeded $67M, up 21% YoY.

  • Burn care revenue reached a quarterly record, with both products at their highest quarterly revenues; full-year burn care growth was in the ~50% range.

  • Net income tripled YoY; adjusted EBITDA rose nearly 50% to almost $25M, with strong operating and free cash flow.

MACI commercial momentum

  • 2026 growth drivers include a sales force expanded 30% from Jan. 1, commercial excellence initiatives, and MACI Arthro momentum; initiatives target deeper surgeon penetration and the midterm $500M revenue goal.

  • Surgeon segmentation uses qualifying-procedure data to focus reps on high-potential practices; standardized playbooks address biopsy volume, implant conversion, administrative barriers, and clinical education.

  • Biopsy growth increasingly reflects both more surgeons biopsying and more biopsies per surgeon; aggregate conversion is ~1/3 over 18 months to two years, while experienced, high-volume users tend to reach ~50%.

  • New territories led biopsy growth through Q3 2026; management expects biopsies to convert over subsequent quarters, with new-rep cohorts showing stronger growth in years two and three and no observed pull-forward.

  • MACI Arthro-trained surgeons include new MACI users; Arthro-only surgeons are starting biopsies and implants, with adoption also creating a halo for MACI open procedures.

UK expansion

  • UK launch is targeted for H2 2027; the marketing application was submitted in Q2 2026, and the MHRA inspected the new facility in Q3, with GMP certification expected before year-end 2026.

  • NICE accepted MACI for a single technology appraisal; reimbursement and regulatory tracks are expected to converge in early H2 2027, supporting a 2027 launch target.

  • NHS treatment is concentrated in about a dozen joint-preservation centers, with a modest training requirement; UK revenue is viewed primarily as a 2028 driver given biopsy-to-implant timing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Vericel earnings date

Logotype for Vericel Corporation
Q4 202625 Feb, 2027
Vericel
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Vericel earnings date

Logotype for Vericel Corporation
Q4 202625 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Vericel Corporation is a biopharmaceutical company focused on developing and manufacturing advanced cell therapies for patients with severe diseases and injuries. The company’s products include autologous cell therapies used in the treatment of cartilage defects, burns, and other medical conditions. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.